Neurocrine Biosciences Inc. (NBIX) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Neurocrine Biosciences Inc. (NBIX) advanced +0.58% to $146.38, trading at 38% of its 52-week range ($122.14 – $186.12). High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of educational resources designed to help healthcare providers strengthen their understanding of classic congenital adrenal hyperplasia. The offering
Tokyo, Japan and Cambridge, UK, 30 October 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter ended 30 Septem
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of Oc
Neurocrine (NBIX) offers affordable growth: strong EPS/revenue gains, reasonable valuation, solid profitability, and a debt-free balance sheet.
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with INGRE
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
Neurocrine's expanding drug portfolio could drive substantial growth through 2031.
Neurocrine Biosciences reported an expert publication on hyperphagia in Prader Willi syndrome that frames the condition as a complex neurobiological disorder and highlights VYKAT XR as the first FDA approved therapy for
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +21.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NBIX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NBIX. Explore sector supply chains on /butterfly.
Across 188 tracked Health Care securities in the Roarable RQD universe, Neurocrine Biosciences Inc. (NBIX) ranks #44 by composite RQD confidence (73/100, grade B) and #81 by equity capitalization ($14.88B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with NBIX at 73/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NBIX
ACTIVE
Neurocrine Biosciences Inc. | B | 73/100 | 31.1x | 96.0% | 15.7% | +0.58% | $14.88B | Benchmark Subject |
| HALO Halozyme Therapeutics Inc. | B | 75/100 | 47.0x | 83.6% | 18.0% | +0.88% | $14.89B | /halo-vs-nbix → |
| EXEL Exelixis Inc. | A | 89/100 | 21.0x | 96.0% | 35.1% | -0.12% | $16.40B | /exel-vs-nbix → |
| TWST Twist Bioscience Corporation | D+ | 52/100 | — | 94.2% | -11.7% | 0.00% | $11.50B | /twst-vs-nbix → |
| TECH Bio-Techne Corp | B | 72/100 | 155.3x | 64.8% | 3.4% | +0.03% | $11.40B | /tech-vs-nbix → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neurocrine Biosciences Inc. (NBIX) reported GAAP revenue of $2.86B (+21.4% vs. FY2024 revenue of $2.36B , and +51.6% cumulative change since FY2023) , GAAP net income of $478.6M, operating cash flow of $782.7M, and free cash flow of $748.7M (+34.4% YoY). On the balance sheet, NBIX closed FY2025 with $4.63B in total assets against $620.3M in total debt (Altman Z-Score: 8.13, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.86B | $478.6M | $782.7M | $748.7M | $4.63B | $620.3M |
| FY2024 (FY) | 2024-12-31 | $2.36B | $341.3M | $595.4M | $557.2M | $3.72B | $508.1M |
| FY2023 (FY) | 2023-12-31 | $1.89B | $249.7M | $389.9M | $305.0M | $8.18B | $1.91B |
As of 2026-11-01, Neurocrine Biosciences Inc. (NASDAQ: NBIX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $146.38 (+0.58% 1D, market cap $14.88B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 188 tracked Health Care issuers, NBIX ranks #44 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NBIX carries a Roarable B (73/100 RQD), trailing P/E of 31.1x, gross margin of 96.0%, and ROIC of 15.7%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B) and EXEL (Exelixis Inc.) posts a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
Per NBIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914475), Neurocrine Biosciences Inc. generated $2.86B in revenue (+21.4% YoY), $478.6M in net income, and $748.7M in free cash flow against $4.63B in total assets and $620.3M in total debt. Key quantitative strengths: Strong cash generator (96% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
NBIX last traded at $146.38 (+0.58% on volume of 831,620 shares), positioning the stock -0.09% below its 50-day simple moving average ($146.51) and -0.72% below its 200-day simple moving average ($147.44). Across its 52-week range of $122.14 to $186.12, NBIX sits at the 37.9% percentile with a 14-day RSI of 56.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($139.35 to $153.41).
Why NBIX Stock advanced +0.58% Today — RQD Quant Desk Flash. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support.